Skip to content

Discontinued — last reported Q4 '23

Gross Profit at other companies

Pfizer logo
PfizerPFE
$10.9B+0.3%
AbbVie logo
AbbVieABBV
$10.78B+15.4%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$28.93M+338%
Gilead Sciences logo
Gilead SciencesGILD
$5.52B+7.6%
Incyte logo
IncyteINCY
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

The official record: SELLAS Life Sciences Group, Inc.’s 10-K, filed March 28, 2024, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s gross profit?
SELLAS Life Sciences Group, Inc. (SLS) reported gross profit of $0 in Q4 2023.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s gross profit?
Over 2 years (2021 to 2023), SELLAS Life Sciences Group, Inc.'s gross profit has grown at a -100.0% compound annual growth rate (CAGR), from $7.4M to $0.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.